Published in Hematol Oncol Clin North Am on February 01, 2014
Phase 3 Frontline Therapy Trial in Patients With Advanced Classical Hodgkin Lymphoma | NCT01712490
EBV CTLs Expressing CD30 Chimeric Receptors For CD 30+ Lymphoma (CARCD30) | NCT01192464
A Study to Assess AFM13 in Patients With Hodgkin Lymphoma | NCT01221571
HD18 for Advanced Stages in Hodgkins Lymphoma | NCT00515554
Epstein Barr Virus (EBV) Specific Cytotoxic T-Cells, Relapsed Lymphoma, ANGEL | NCT00058617
Study of MGCD0103 (MG-0103) in Patients With Relapsed or Refractory Hodgkin's Lymphoma | NCT00358982
Phase II R-ABVD Versus ABVD for Advanced Stage Classical Hodgkin Lymphoma | NCT00654732
Study of Rituximab and Brentuximab Vedotin for Relapsed Classical Hodgkin Lymphoma | NCT01900496
Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma | NCT00540007
Rituximab and ABVD for Hodgkin's Patients | NCT00504504
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma | NCT00516217
A Phase II Study of MDX-060 in Subjects With Relapsed or Refractory Hodgkin's Disease | NCT00284804
Safety and Efficacy Study of TNX-650 to Treat Refractory Hodgkin's Lymphoma | NCT00441818
The favorable role of homozygosity for killer immunoglobulin-like receptor (KIR) A haplotype in patients with advanced-stage classic Hodgkin lymphoma. J Hematol Oncol (2016) 0.75
HLA-G expression and role in advanced-stage classical Hodgkin lymphoma. Eur J Histochem (2016) 0.75
Simultaneous occurrence of Hodgkin's lymphoma and multiple myeloma: A case report and review of the literature. Oncol Lett (2016) 0.75
Pediatric Hodgkin lymphoma: biomarkers, drugs, and clinical trials for translational science and medicine. Oncotarget (2016) 0.75
Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med (2010) 8.74
Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol (2012) 6.78
Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med (2010) 5.92
Histone deacetylases and cancer. Oncogene (2007) 4.30
Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood (2007) 3.94
Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease. J Exp Med (2004) 3.57
Circulating clonotypic B cells in classic Hodgkin lymphoma. Blood (2009) 3.34
The biology of Hodgkin's lymphoma. Nat Rev Cancer (2008) 3.31
T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood (2009) 2.79
Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study. J Clin Oncol (2012) 2.65
Breast cancer risk in female survivors of Hodgkin's lymphoma: lower risk after smaller radiation volumes. J Clin Oncol (2009) 2.42
Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. Clin Cancer Res (2012) 2.39
The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. Proc Natl Acad Sci U S A (2007) 2.31
A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol (2010) 2.27
Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes. J Clin Oncol (2012) 2.23
PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. Blood (2008) 2.15
Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects. J Biol Chem (1999) 2.14
Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation. Cancer Immunol Immunother (2008) 1.95
Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment. J Clin Oncol (2011) 1.94
Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse. Ann Oncol (2005) 1.88
High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltratein Hodgkin's lymphoma. Am J Pathol (1999) 1.78
Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial. Lancet Oncol (2011) 1.75
Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome. Blood (2008) 1.74
Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4. Clin Cancer Res (2011) 1.70
Inhibition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in hematologic malignancies. Curr Treat Options Oncol (2006) 1.70
Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines. Blood (2008) 1.69
A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies. Clin Cancer Res (2011) 1.67
Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma. Blood (2012) 1.64
The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape. J Pathol (2010) 1.55
Late effects in the era of modern therapy for Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program (2011) 1.54
New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group. J Clin Oncol (2002) 1.53
A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer (2003) 1.49
Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial. Blood (2012) 1.49
MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival. Blood (2003) 1.48
Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center. Haematologica (2012) 1.46
Effect of alemtuzumab on neoplastic B cells. Haematologica (2004) 1.46
Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant. Leuk Lymphoma (2013) 1.45
A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol (2009) 1.44
A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood (2011) 1.44
Epigenetic modifiers: basic understanding and clinical development. Clin Cancer Res (2009) 1.38
Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. J Clin Oncol (2007) 1.38
Epigenetic processes play a major role in B-cell-specific gene silencing in classical Hodgkin lymphoma. Blood (2005) 1.24
Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma. Blood (2012) 1.23
Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma. Blood (2012) 1.19
Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin's lymphoma following autologous stem cell transplantation. Bone Marrow Transplant (2008) 1.14
Epstein-Barr virus, cytokines, and inflammation: a cocktail for the pathogenesis of Hodgkin's lymphoma? Exp Hematol (2006) 1.12
Galectin-1 mediated suppression of Epstein-Barr virus specific T-cell immunity in classic Hodgkin lymphoma. Blood (2007) 1.12
Gene expression profiling of microdissected Hodgkin Reed-Sternberg cells correlates with treatment outcome in classical Hodgkin lymphoma. Blood (2012) 1.11
Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206. Leuk Lymphoma (2007) 1.08
Differential expression and function of CD80 (B7-1) and CD86 (B7-2) on human peripheral blood monocytes. Immunology (1996) 1.06
Brentuximab vedotin combined with donor lymphocyte infusions for early relapse of Hodgkin lymphoma after allogeneic stem-cell transplantation induces tumor-specific immunity and sustained clinical remission. J Clin Oncol (2012) 1.06
Expression of CCR5 receptors on Reed-Sternberg cells and Hodgkin lymphoma cell lines: involvement of CCL5/Rantes in tumor cell growth and microenvironmental interactions. Int J Cancer (2008) 1.04
Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma. Cancer (2008) 1.01
Recent Advances in the Pathobiology of Hodgkin's Lymphoma: Potential Impact on Diagnostic, Predictive, and Therapeutic Strategies. Adv Hematol (2011) 0.98
Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: analysis of 280 patients from the French registry. Société Française de Greffe de Moëlle. Bone Marrow Transplant (1997) 0.98
The molecular pathogenesis of Hodgkin lymphoma. Histopathology (2011) 0.97
Biologic features of Hodgkin lymphoma and the development of biologic prognostic factors in Hodgkin lymphoma: tumor and microenvironment. Leuk Lymphoma (2008) 0.97
Functional coexpression of Interleukin (IL)-7 and its receptor (IL-7R) on Hodgkin and Reed-Sternberg cells: Involvement of IL-7 in tumor cell growth and microenvironmental interactions of Hodgkin's lymphoma. Int J Cancer (2009) 0.96
A phase-I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin's lymphoma. Blood (1997) 0.96
Baseline serum TARC levels predict therapy outcome in patients with Hodgkin lymphoma. Am J Hematol (2012) 0.95
Risk of therapy-related secondary leukemia in Hodgkin lymphoma: the Stanford University experience over three generations of clinical trials. J Clin Oncol (2013) 0.94
NF-kappaB-independent down-regulation of XIAP by bortezomib sensitizes HL B cells against cytotoxic drugs. Blood (2006) 0.94
The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma. Blood Cancer J (2011) 0.93
Phase I study of bortezomib plus ICE (BICE) for the treatment of relapsed/refractory Hodgkin lymphoma. Br J Haematol (2011) 0.92
A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517. Leuk Lymphoma (2011) 0.91
Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism. Ann Oncol (2010) 0.90
Class I histone deacetylases 1, 2 and 3 are highly expressed in classical Hodgkin's lymphoma. Expert Opin Ther Targets (2010) 0.90
The role of CD40/CD40L and interferon regulatory factor 4 in Hodgkin lymphoma microenvironment. Leuk Lymphoma (2011) 0.86
Early thymus and activation-regulated chemokine (TARC) reduction and response following panobinostat treatment in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplant. Leuk Lymphoma (2013) 0.84
Autophagy controls everolimus (RAD001) activity in mantle cell lymphoma. Autophagy (2012) 0.83
The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance). Leuk Lymphoma (2013) 0.81
Costimulatory molecules (CD80 and CD86) on Reed-Sternberg cells are associated with the proliferation of background T cells in Hodgkin's disease. Pathol Int (1998) 0.79
The role of CD30, CD40 and CD95 in the regulation of proliferation and apoptosis in classical Hodgkin's lymphoma. Pathology (2003) 0.78
The emerging role of PET in Hodgkin lymphoma patients receiving autologous stem cell transplant. Expert Rev Hematol (2012) 0.77
Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med (2013) 4.96
Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol (2012) 4.41
Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial. Blood (2013) 1.72
Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. Blood (2008) 1.55
Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). J Clin Oncol (2004) 1.48
Prognostic factors in primary cutaneous anaplastic large cell lymphoma: characterization of clinical subset with worse outcome. Arch Dermatol (2009) 1.46
Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248. Clin Cancer Res (2007) 1.33
Non-Hodgkin lymphoma of the breast. Cancer (2007) 1.27
Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. J Hematol Oncol (2014) 1.18
MicroRNAs are independent predictors of outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. Clin Cancer Res (2011) 1.17
Extranodal natural killer/T-cell lymphoma: current concepts in biology and treatment. Leuk Lymphoma (2009) 1.13
A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. Br J Haematol (2014) 1.11
Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma. Blood (2012) 1.07
CD40 pathway activation status predicts response to CD40 therapy in diffuse large B cell lymphoma. Sci Transl Med (2011) 1.06
Staging accuracy in mycosis fungoides and sezary syndrome using integrated positron emission tomography and computed tomography. Arch Dermatol (2006) 1.03
Management of T-cell and natural-killer-cell neoplasms in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol (2009) 0.99
Treatment of mantle cell lymphoma: current approach and future directions. Crit Rev Oncol Hematol (2006) 0.97
Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Leuk Lymphoma (2015) 0.95
Sézary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). J Am Acad Dermatol (2010) 0.94
Cutaneous involvement by angioimmunoblastic T-cell lymphoma: a unique histologic presentation, mimicking an infectious etiology. J Cutan Pathol (2006) 0.92
Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis. J Clin Oncol (2013) 0.91
The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. Br J Haematol (2013) 0.91
Interim-treatment quantitative PET parameters predict progression and death among patients with Hodgkin's disease. Radiat Oncol (2012) 0.91
Management of B-cell non-Hodgkin lymphoma in Asia: resource-stratified guidelines. Lancet Oncol (2013) 0.90
Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies. Cancer Chemother Pharmacol (2014) 0.89
Risk stratification in extranodal natural killer/T-cell lymphoma. Expert Rev Anticancer Ther (2010) 0.84
Lymphoma cell VEGFR2 expression detected by immunohistochemistry predicts poor overall survival in diffuse large B cell lymphoma treated with immunochemotherapy (R-CHOP). Br J Haematol (2009) 0.83
Cancer vaccines and T cell therapy. Biol Blood Marrow Transplant (2012) 0.83
A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors. J Hematol Oncol (2014) 0.82
Brentuximab vedotin in transplant-naive patients with relapsed or refractory hodgkin lymphoma: analysis of two phase I studies. Oncologist (2012) 0.81
ACR Appropriateness Criteria Pediatric Hodgkin Lymphoma. Pediatr Blood Cancer (2014) 0.80
Targeted therapy in relapsed classical hodgkin lymphoma. J Natl Compr Canc Netw (2013) 0.80
Indolent primary cutaneous B-cell lymphoma: experience using systemic rituximab. J Am Acad Dermatol (2008) 0.78
Splenic diffuse large B-cell lymphoma in a patient with type 1 Gaucher disease: Diagnostic and therapeutic challenges. Ann Hematol (2006) 0.77
ACR Appropriateness Criteria® Hodgkin Lymphoma-Favorable Prognosis Stage I and II. Am J Clin Oncol (2016) 0.77
ACR Appropriateness Criteria® on Hodgkin's lymphoma-unfavorable clinical stage I and II. J Am Coll Radiol (2011) 0.76
Dynamic CD8 T-cell responses to tumor-associated Epstein-Barr virus antigens in patients with Epstein-Barr virus-negative Hodgkin's disease. Oncol Res (2009) 0.76
ACR Appropriateness Criteria: Localized nodal indolent lymphoma. Oncology (Williston Park) (2013) 0.76
ACR Appropriateness Criteria® Diffuse Large B-Cell Lymphoma. Am J Clin Oncol (2015) 0.75
Targeting CD40 in Waldenström's macroglobulinemia. Clin Lymphoma Myeloma (2009) 0.75
ACR Appropriateness Criteria® Hodgkin Lymphoma-Unfavorable Clinical Stage I and II. Am J Clin Oncol (2016) 0.75
Lymphoma in pregnancy initially diagnosed as vaginal intraepithelial neoplasia and lichen planus. Obstet Gynecol (2011) 0.75